Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 779 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Transplant Care Clear all
Completed Not applicable Interventional Results available

Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation

NCT02736227
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus Withdrawal and Everolimus Monotherapy
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

NCT00846131
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib, Yttrium-90 (Y-90)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Not applicable Interventional Results available

Using mTOR Inhibitors in the Prevention of BK Nephropathy

NCT01649609
View directory record Official record
Conditions
BK Viremia, BK Nephropathy
Interventions
Tacrolimus, Mycophenolate acid, Sirolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 30, 2026, 2:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

NCT04946721
View directory record Official record
Conditions
Dry Eye Disease, oGVHD
Interventions
The standard care exam and biological specimens' collection
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1Phase 2 Interventional

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

NCT04990323
View directory record Official record
Conditions
High Risk Myeloid Malignancies, Cord Blood Transplant
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
0 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Withdrawn Not applicable Interventional

Rib Microtia and the Erector Spinae Plane (ESP) Block

NCT03729427
View directory record Official record
Conditions
Microtia, Congenital, Microtia, Anesthesia, Local, Anesthesia
Interventions
Erector Spinae Plane Block
Procedure
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

NCT01064791
View directory record Official record
Conditions
Renal Transplantation
Interventions
sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Not applicable Interventional Results available

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

NCT02575079
View directory record Official record
Conditions
Central Line Associated Bloodstream Infections (CLABSI), Bone Marrow Transplant
Interventions
Parafilm
Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Not applicable Interventional

Del Nido Cardioplegia Randomized Trial

NCT02442050
View directory record Official record
Conditions
Cardiac Perfusion
Interventions
del Nido solution, Blood-based cardioplegia
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
19 Years to 79 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NSS-2-BRIDGE Study for Total Knee and Hip Arthroplasties, Bariatric, and Kidney Transplant Surgeries

NCT03834142
View directory record Official record
Conditions
Acute Pain, Arthropathy of Knee, Arthropathy of Hip, Pain, Postoperative, Kidney Transplant Donor, Bariatric Surgery Candidate
Interventions
NSS-2 Bridge
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

NCT00278525
View directory record Official record
Conditions
SYSTEMIC SCLERODERMA
Interventions
standard of care, stem cell transplantation
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

A Study of TCD601 in de Novo Renal Transplant Recipients

NCT05669001
View directory record Official record
Conditions
Renal Transplantation
Interventions
TCD601, belatacept, ATG, TAC, MPA, Corticosteroids
Biological · Drug
Lead sponsor
ITB-Med LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Sacramento, California • San Francisco, California • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Recruiting Not applicable Interventional

Changes of Soft Tissue Grafting: A Randomized Study

NCT05633511
View directory record Official record
Conditions
Gingival Recession
Interventions
Split Mouth Design
Procedure
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Not listed Phase 2 Interventional

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

NCT04116775
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Fecal microbiota transplant, Pembrolizumab, Enzalutamide
Biological · Drug
Lead sponsor
Julie Graff, MD
Federal
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Not yet recruiting Phase 2 Interventional

Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

NCT07715734
View directory record Official record
Conditions
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
Interventions
Cemiplimab, Prednisone, Sirolimus, Cetuximab (EGFR inhibitor)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Not applicable Interventional

Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure

NCT02128802
View directory record Official record
Conditions
Severe Obesity, Renal Failure
Interventions
Gastric Bypass, Weight Loss Program
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Not yet recruiting Not applicable Interventional

Safety Study of Microlyte DualGuard

NCT07695688
View directory record Official record
Conditions
Wound Closure, Wound Care
Interventions
Microlyte DualGuard, Allevyn Foam (Standard of Care Control)
Device
Lead sponsor
Imbed Biosciences
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

NCT05130827
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Plinabulin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Early Phase 1 Interventional

TPO-Mimetic Use in Children for Hematopoietic Failure

NCT04478227
View directory record Official record
Conditions
Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions
Romiplostim
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
0 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT01065935
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, Normal Saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

NCT03121014
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine, Busulfan, ATG, Total Marrow Irradiation, Stem Cell Product Infusion, Tacrolimus, Methotrexate
Drug · Radiation · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Not applicable Interventional Results available

BRIDGE Device for Post-operative Pain Control

NCT03265249
View directory record Official record
Conditions
Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
Interventions
BRIDGE device
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Sep 30, 2026, 2:33 AM EDT